The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Safety analysis of DeLLphi-304: tarlatamab vs chemotherapy in small cell lung cancer
Martin Schuler, MD, University Hospital Essen, Essen, Germany, discusses the detailed safety findings from the Phase III DeLLphi-304 trial (NCT05740566), the first study to show superiority of the DLL3-targeted bispecific T-cell engager tarlatamab over standard chemotherapy in previously treated small cell lung cancer (SCLC). The analysis demonstrated improved overall and progression-free survival, fewer severe adverse events, and manageable cytokine release syndrome and neurotoxicity, confirming tarlatamab as a safe and feasible new standard for second-line SCLC treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
